{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:12:47Z","timestamp":1793646767455,"version":"4.5.1"},"reference-count":24,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction &amp; Objective: Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), with limited treatment options for steroid-resistant cases. Ruxolitinib, a JAK1\/2 inhibitor, has shown promise in treating steroid-resistant acute (aGVHD), chronic (cGVHD), and overlap GVHD (oGVHD), but real-world data remain limited. This study evaluated the real-world efficacy and safety of ruxolitinib in allo-HSCT patients with steroid-resistant GVHD. Materials &amp; Methods: This retrospective, multicenter study included adult patients treated with ruxolitinib for Grade II or higher aGVHD or moderate-to-severe cGVHD at nine centers in Turkey (2017\u20132024). Clinical characteristics, treatment responses, and adverse events were recorded. Primary outcomes were overall response rate (ORR) and overall survival (OS). Results: Among 80 patients (mean age: 39.3 \u00b1 13.3 years; 60 males), 39 had aGVHD, 68 cGVHD, and 15 oGVHD. The ORR was 72 of 80 patients (90.0%) (complete response: 37 of 80 [46.3%], partial response: 35 of 80 [43.8%]). The 1-year and 2-year OS rates were 91.3% and 82.5%. Severe cGVHD (p &lt; 0.001) and lack of response to ruxolitinib (p = 0.018) were associated with reduced OS. Adverse events included infections in 40 of 80 patients (50.0%), cytopenias in 23 of 80 (28.7%), and cytomegalovirus reactivation in 20 of 80 (25.0%). Conclusion: In this retrospective multicenter cohort, ruxolitinib was associated with high response rates in steroid-refractory GVHD, while disease severity remained a key determinant of survival, and findings should be interpreted as exploratory.<\/jats:p>","DOI":"10.3390\/jcm15052088","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:49:42Z","timestamp":1773071382000},"page":"2088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3216-482X","authenticated-orcid":false,"given":"Mehmet","family":"Bak\u0131rta\u015f","sequence":"first","affiliation":[{"name":"Department of Hematology, Tekirda\u011f Dr. \u0130smail Fehmi Cumal\u0131o\u011flu City Hospital, Tekirda\u011f 59030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhami","family":"Berber","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, \u0130non\u00fc University, Malatya 44280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130pek Y\u00f6nal","family":"Hindilerden","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, \u0130stanbul University \u0130stanbul Medical Faculty, \u0130stanbul 34100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-2966","authenticated-orcid":false,"given":"\u015eebnem","family":"\u0130zmir G\u00fcner","sequence":"additional","affiliation":[{"name":"Department of Adult Bone Marrow Transplantation Unit & Hematology, Hisar Intercontinental Hospital, \u0130stanbul 34100, Turkey"},{"name":"Division of Hematology, Department of Internal Medicine, \u0130stanbul Geli\u015fim University, \u0130stanbul 34100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-8104","authenticated-orcid":false,"given":"Ay\u015fe","family":"Uysal","sequence":"additional","affiliation":[{"name":"Hematology Department, School of Medicine, F\u0131rat University, Elaz\u0131\u011f 23000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4636-3590","authenticated-orcid":false,"given":"\u00d6mer","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Unit, \u015ei\u015fli Kolan International Hospital Istanbul, \u0130stanbul 34100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-8984","authenticated-orcid":false,"given":"Burcu","family":"Aslan Cand\u0131r","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ad\u0131yaman Training and Research Hospital, Ad\u0131yaman 02200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Eser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medikal Park Antalya Hospital, Antalya 07160, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seval","family":"Akp\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Tekirda\u011f Nam\u0131k Kemal University, Tekirda\u011f 59030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-344X","authenticated-orcid":false,"given":"Soykan","family":"Bi\u00e7im","sequence":"additional","affiliation":[{"name":"Malatya Education and Research Hospital, University of Health Sciences, Malatya 44280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011f\u00e7e Nur","family":"Yi\u011feno\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-663X","authenticated-orcid":false,"given":"Turgay","family":"Ula\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Turgut","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Tekirda\u011f Nam\u0131k Kemal University, Tekirda\u011f 59030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, \u0130non\u00fc University, Malatya 44280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology & Apheresis Unit, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara 06200, Turkey"},{"name":"Division of Hematology, Department of Internal Medicine, School of Medicine, Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation","volume":"24","author":"Zabelina","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41409-024-02266-7","article-title":"Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients","volume":"59","author":"Zhang","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.29271\/jcpsp.2022.09.1225","article-title":"Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant","volume":"32","author":"Javed","year":"2022","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00277-020-04273-2","article-title":"Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide","volume":"100","author":"Zhao","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41409-024-02249-8","article-title":"Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease","volume":"59","author":"Murray","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: A multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s00277-023-05361-9","article-title":"Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: A retrospective study","volume":"102","author":"Liu","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_8","first-page":"16435","article-title":"Ruxolitinib is highly effective in steroid-resistant graft-versus-host disease: Real-world data from a single center","volume":"133","author":"Helbig","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1007\/s00277-024-05703-1","article-title":"The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis","volume":"103","author":"Wang","year":"2024","journal-title":"Ann Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"De Togni, E., Cole, O., and Abboud, R. (2024). Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1304065"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"528.e1","DOI":"10.1016\/j.jtct.2024.02.018","article-title":"Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease","volume":"30","author":"Cook","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8163780","DOI":"10.1155\/2019\/8163780","article-title":"Ruxolitinib for Therapy of Graft-versus-Host Disease","volume":"2019","author":"Neumann","year":"2019","journal-title":"BioMed. Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e15195","DOI":"10.1111\/ctr.15195","article-title":"When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multicenter research","volume":"38","author":"Ren","year":"2024","journal-title":"Clin. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.bbmt.2020.01.012","article-title":"Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation","volume":"26","author":"Zhao","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network (2016). The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol. Blood Marrow Transplant., 22, 1747\u20131757.","DOI":"10.1016\/j.bbmt.2016.07.003"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/s41409-023-02005-4","article-title":"Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3-4 steroid-refractory acute graft-versus-host disease: A registered clinical trial (NCT05021276)","volume":"58","author":"Zhou","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41409-024-02252-z","article-title":"Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: A systematic review and individual patient data meta-analysis","volume":"59","author":"Baccelli","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.56875\/2589-0646.1111","article-title":"A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes","volume":"17","author":"Linn","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_22","first-page":"2771","article-title":"Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: A REACH2 analysis","volume":"141","author":"Niederwieser","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.17700","article-title":"Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease\u2014A real-world outcomes analysis","volume":"195","author":"Abedin","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12967-023-04731-1","article-title":"Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease","volume":"21","author":"Bonig","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:11:35Z","timestamp":1773072695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15052088"],"URL":"https:\/\/doi.org\/10.3390\/jcm15052088","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}